Watson buys rights to HRT (hormone replacement therapy) product:
This article was originally published in Clinica
TheraTech, a wholly owned subsidiary of Watson Pharmaceuticals, has acquired marketing and distribution rights to the Alora oestradiol transdermal system from Procter & Gamble, which held exclusive rights since the product's US launch in 1997. Alora will now be marketed through Corona, California-based Watson's Women's Health division. TheraTech also bought back the rights to a development-stage oestradiol and progestin combination patch, while P&G retains global marketing and development rights to a range of female transdermal testosterone products.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.